Long

$GMTX (SPACs)

Description: Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Industry: Biotechnology
Beyond Technical AnalysisbreakoutbreakoutsignalbuybuysignalChart PatternssignalsspacstrengthsupportWave Analysis

Disclaimer